Výsledky vyhledávání

Autor: Alan S. Pickard, Lauren McCann, Cora N. Sternberg, L. Antras, R. Hodge, A. Guerin, Maureen P. Neary, David Cella, N. Mishagina, Mei Sheng Duh

Publikováno v: European Journal of Cancer. 48:311-323

In a double-blind, randomised phase III trial of advanced renal cell carcinoma patients, pazopanib 800mg QD (n=290) versus placebo (n=145) significantly prolonged progression-free survival (hazard ratio (HR)=0.46, 95% confidence interval [CI] 0.34-0.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3141c6581027f333c8c1ceff7c0afa0c
https://doi.org/10.1016/j.ejca.2011.05.017

Zobrazit plný text záznamu

Angiogenesis inhibitor therapies for metastatic renal cell carcinoma: effectiveness, safety and treatment patterns in clinical practice-based on medical chart review

Autor: William Oh, L. Antras, Sujata S. Jayawant, Andrew Percy, David F. McDermott, Toni K. Choueiri, Jessica M. Clement, Miranda J. Rogers, Si-Tien Wang, Kristina Chen, Maureen P. Neary, Andi Luka, A. J. Brick, Karishma Shah, Mei Sheng Duh, Christabel Kwabi

Publikováno v: BJU International. 105:1247-1254

OBJECTIVE To assess the effectiveness, safety, and treatment patterns of anti-angiogenic agents in metastatic renal cell carcinoma (mRCC) in tertiary clinical practice settings. PATIENTS AND METHODS We retrospectively reviewed the medical records in

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dfac6a61359decdae09503b91b5abba5
https://doi.org/10.1111/j.1464-410x.2009.08972.x

Zobrazit plný text záznamu

Cost implications of IV versus oral anti-angiogenesis therapies in patients with advanced renal cell carcinoma: retrospective claims database analysis*

Autor: Toni K. Choueiri, Douglas Rodermund, William Oh, Mei Sheng Duh, L. Antras, Andrée-Anne Fournier, Maureen P. Neary, Ellison Dial

Publikováno v: Current Medical Research and Opinion. 25:2081-2090

Angiogenesis inhibitors (AI) are promising novel treatments for patients with renal cell carcinoma (RCC). However, IV therapy may impose infection risk from IV catheters, and will include increased costs due to administration and transportation costs

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2da4aa080aeff34f72841af474f79268
https://doi.org/10.1185/03007990903084800

Zobrazit plný text záznamu

Risk of renal impairment after treatment with ibandronate versus zoledronic acid: a retrospective medical records review

Autor: Neil Wintfeld, Mei Sheng Duh, M. A. Smith, Ingo Diel, Jesse Green, L. Antras, Maureen P. Neary, Hubert Köppler, Rudolf Weide

Publikováno v: Supportive Care in Cancer. 17:719-725

This retrospective study compared renal impairment rates in breast cancer, multiple myeloma, prostate cancer and non-small cell lung cancer patients treated with ibandronate or zoledronic acid.Medical records in two German oncology clinics from May 2

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6d2b596a30266458bb42bcb50dde1a3d
https://doi.org/10.1007/s00520-008-0553-7

Zobrazit plný text záznamu

The risk of renal impairment in hormone-refractory prostate cancer patients with bone metastases treated with zoledronic acid

Autor: William Oh, Timothy J. Daskivich, Kevin Proctor, Mei Sheng Duh, M. A. Smith, Carolyn Evan, Lauren K. Tormey, Maureen P. Neary, Mari Nakabayashi, L. Antras

Publikováno v: Cancer. 109:1090-1096

BACKGROUND Bisphosphonates have been used to treat bone metastases in hormone-refractory prostate cancer (HRPC), but certain agents have been associated with renal toxicity. For this observational study, the authors assessed the risk of renal impairm

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::90d5d5cdd76f0accc79aa12140f9dfa6
https://doi.org/10.1002/cncr.22504

Zobrazit plný text záznamu

Predictors of response to sequential sunitinib and the impact of prior VEGF-targeted drug washout in patients with metastatic clear-cell renal cell carcinoma

Autor: William Oh, Michael B. Atkins, Sujata S. Jayawant, David F. McDermott, Mei Sheng Duh, Jonathan E. Rosenberg, Barry Fortner, L. Antras, Toni K. Choueiri, Daniel C. Cho, Aymen Elfiky, Kristina Chen

Publikováno v: Urologic oncology. 29(6)

To identify factors that can be used to identify metastatic clear cell RCC patients more likely to benefit from sequential sunitinib.We identified patients who failed sorafenib or bevacizumab and subsequently received sunitinib. We looked at objectiv

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::52965f43a79a376e142cd111f0f2de9f
https://pubmed.ncbi.nlm.nih.gov/20451414

Zobrazit plný text záznamu

Symptom assessment in relapsed small cell lung cancer: cross-validation of the patient symptom assessment in lung cancer instrument

Autor: L. Antras, Maureen P. Neary, Mary O'Brien, Lei Chen, Mei Sheng Duh

Publikováno v: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 3(10)

IntroductionLung cancer symptoms can be burdensome for patients with small cell lung cancer (SCLC). Patient Symptom Assessment in Lung Cancer (PSALC), a self-report scale for assessing SCLC symptom burden, was developed and validated previously using

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2bebe495c33c551af9ce983516aa5289
https://pubmed.ncbi.nlm.nih.gov/18827610

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání